ImmunID, the immune companion diagnostics for precision medicine company, has announced that a collaborative work on prediction of response to the anti-PD1 and anti-CTLA-4 immune checkpoint inhibitors in melanoma using ImmunTraCkeR has been selected for a poster presentation during the American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago, IL on June 3-7, 2016. These results we generated in collaboration with Zurich University Hospital (Switzerland) and the NKI (The Netherlands), two leading European clinical centres in Immuno-Oncology.
With more than 30,000 attendees, the ASCO Annual Meeting is one of the largest educational and scientific events in the oncology community. The five-day event provides a venue for physicians and scientists to present research results to a global audience of oncology professionals. Clinical trial results and updates presented at ASCO's Annual Meeting represent the extent of progress made each year in the fight against cancer.
